Literature DB >> 30810435

Beta 2-microglobulin regulates amyloid precursor-like protein 2 expression and the migration of pancreatic cancer cells.

Bailee H Sliker1,2, Benjamin T Goetz1,2, Haley L Peters1,2, Brittany J Poelaert1,2, Gloria E O Borgstahl1,2,3,4, Joyce C Solheim1,2,3,5.   

Abstract

Beta 2-microglobulin (β2m) is a component of the major histocompatibility complex (MHC) class I molecule, which presents tumor antigens to T lymphocytes to trigger cancer cell destruction. Notably, β2m has been reported as persistently expressed, rather than down regulated, in some tumor types. For renal cell and oral squamous cell carcinomas, β2m expression has been linked to increased migratory capabilities. The migratory ability of pancreatic cancer cells contributes to their metastatic tendencies and lethal nature. Therefore, in this study, we examined the impact of β2m on pancreatic cancer cell migration. We found that β2m protein is amply expressed in several human pancreatic cancer cell lines (S2-013, PANC-1, and MIA PaCa-2). Reducing β2m expression by short interfering RNA (siRNA) transfection significantly slowed the migration of the PANC-1 and S2-013 cancer cell lines, but increased the migration of the MIA PaCa-2 cell line. The amyloid precursor-like protein 2 (APLP2) has been documented as contributing to pancreatic cancer cell migration, invasiveness, and metastasis. We have previously shown that β2m/HLA class I/peptide complexes associate with APLP2 in S2-013 cells, and in this study we also detected their association in PANC-1 cells but not MIA PaCa-2 cells. In addition, siRNA down regulation of β2m expression diminished the expression of APLP2 in S2-013 and PANC-1 but heightened the level of APLP2 in MIA PaCa-2 cells, consistent with our migration data and co-immunoprecipitation data. Thus, our findings indicate that β2m regulates pancreatic cancer cell migration, and furthermore suggest that APLP2 is an intermediary in this process.

Entities:  

Keywords:  Amyloid precursor-like protein 2; HLA class I molecule; beta 2-microglobulin; migration; pancreatic cancer

Year:  2019        PMID: 30810435      PMCID: PMC6606018          DOI: 10.1080/15384047.2019.1580414

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  90 in total

1.  Residue 3 of beta2-microglobulin affects binding of class I MHC molecules by the W6/32 antibody.

Authors:  J J Ladasky; B P Shum; F Canavez; H N Seuánez; P Parham
Journal:  Immunogenetics       Date:  1999-04       Impact factor: 2.846

2.  The amyloid precursor-like protein 2 associates with the major histocompatibility complex class I molecule K(d).

Authors:  M Sester; D Feuerbach; R Frank; T Preckel; A Gutermann; H G Burgert
Journal:  J Biol Chem       Date:  2000-02-04       Impact factor: 5.157

3.  Elastase activity enhances the adhesion of neutrophil and cancer cells to vascular endothelial cells.

Authors:  F Nozawa; M Hirota; A Okabe; M Shibata; T Iwamura; Y Haga; M Ogawa
Journal:  J Surg Res       Date:  2000-12       Impact factor: 2.192

4.  Expression and characterization of the human YWK-II gene, encoding a sperm membrane protein related to the alzheimer betaA4-amyloid precursorprotein.

Authors:  P Huang; S Miao; H Fan; Q Sheng; Y Yan; L Wang; S S Koide
Journal:  Mol Hum Reprod       Date:  2000-12       Impact factor: 4.025

5.  Overexpression of MUC1 reconfigures the binding properties of tumor cells.

Authors:  K M McDermott; P R Crocker; A Harris; M D Burdick; Y Hinoda; T Hayashi; K Imai; M A Hollingsworth
Journal:  Int J Cancer       Date:  2001-12-15       Impact factor: 7.396

6.  Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule.

Authors:  S Satoh; Y Hinoda; T Hayashi; M D Burdick; K Imai; M A Hollingsworth
Journal:  Int J Cancer       Date:  2000-11-15       Impact factor: 7.396

7.  Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia.

Authors:  S Molica; D Levato; N Cascavilla; L Levato; P Musto
Journal:  Eur J Haematol       Date:  1999-02       Impact factor: 2.997

8.  Invasiveness and MMP expression in pancreatic carcinoma.

Authors:  X Yang; E D Staren; J M Howard; T Iwamura; J E Bartsch; H E Appert
Journal:  J Surg Res       Date:  2001-06-01       Impact factor: 2.192

9.  Amyloid precursor-like protein 2 promotes cell migration toward fibronectin and collagen IV.

Authors:  X F Li; G Thinakaran; S S Sisodia; F S Yu
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

10.  The amyloid precursor-like protein 2 and the adenoviral E3/19K protein both bind to a conformational site on H-2Kd and regulate H-2Kd expression.

Authors:  Chantey R Morris; Jason L Petersen; Shanna E Vargas; Heth R Turnquist; Mary M McIlhaney; Sam D Sanderson; Joseph T Bruder; Yik Y L Yu; Hans-Gerhard Burgert; Joyce C Solheim
Journal:  J Biol Chem       Date:  2002-12-27       Impact factor: 5.157

View more
  3 in total

1.  Combined Diagnostic Significance of Preoperative Serum β2-Microglobulin and Routine Blood Test in Patients with High-grade Glioma and Solitary Brain Metastasis.

Authors:  Liwen Li; Xiaomin Bu; Bin Wu; Shuyuan Zhang; Kai Jin; Liang Xia; Caixing Sun
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

2.  Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic Cancer.

Authors:  Brittany J Poelaert; Shelby M Knoche; Alaina C Larson; Poomy Pandey; Parthasarathy Seshacharyulu; Nuzhat Khan; H Carlo Maurer; Kenneth P Olive; Yuri Sheinin; Rizwan Ahmad; Amar B Singh; Surinder K Batra; Satyanarayana Rachagani; Joyce C Solheim
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

Review 3.  Molecular Characteristics of Amyloid Precursor Protein (APP) and Its Effects in Cancer.

Authors:  Han Na Lee; Mi Suk Jeong; Se Bok Jang
Journal:  Int J Mol Sci       Date:  2021-05-08       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.